A Partnership Built on Shared Mission
Resilience Reserve invests in startups that promise to make the world more resilient in some important way. They have backed companies in areas including public health, climate resilience, energy, agriculture, material science, and energy-efficient semiconductors. The fund seeks to be not just a source of capital, but a strategic partner for world-class teams with breakthrough technologies and missions.
Through this investment, Resilience Reserve will hold approximately 18.33% of the shares of the resulting issuer formed pursuant to the proposed qualifying transaction, making it a cornerstone investor in the resulting issuer’s future growth.
Rob Reid, Entrepreneur, Author, and Technology Strategist
Rob Reid is a seasoned entrepreneur, bestselling science-fiction author, and technology investor whose career has spanned streaming media, synthetic biology, AI, and deep-tech innovation. He founded the company behind Rhapsody, which pioneered the unlimited-streaming model that subsequently took over music distribution. He later launched the acclaimed podcast After On, which features in-depth interviews with world-class thinkers, founders, and scientists. A graduate of Stanford and Harvard and a Cairo Fulbright Fellow, Rob brings technical savvy, scientific curiosity, and entrepreneurial experience to all of his work.
Chris Anderson, Global Leader in Ideas and Impact
Chris Anderson brings decades of global leadership and impact-focused entrepreneurship to Resilience Reserve. Best known as the head of TED, he has helped build one of the world’s most influential idea platforms and, through initiatives such as The Audacious Project, has raised more than three billion dollars to support transformative global programs. His work centers on identifying visionary teams and helping them scale solutions that create meaningful, long-term benefit for society.
Management Commentary
“Receiving Rob and Chris’ investment is a major moment for us. They understand the scale of the challenge we are tackling and the opportunity to reshape how public health protects people from infection and airborne disease. Their strategic vision and ability to see around corners will be key as we move to complete the transaction and enter into a new phase of growth.”
, Ehsan Agahi, Executive Chairman
“I’ve been fascinated by the public-health and pandemic-resilience potential of UVC and Far-UVC light since I started researching, presenting, and podcasting about these topics during the COVID crisis. Claranova could soon revolutionize the use of tuned and targeted light as a weapon against disease.”
, Rob Reid
“Claranova’s existing and upcoming products promise to significantly dampen the spread of respiratory diseases in healthcare facilities, schools, and beyond. This could greatly enhance social resilience at all levels of global income.”
, Chris Anderson
Investment Details
The investment was made through a non-brokered private placement of subscription receipts at a price of $0.30 per subscription receipt, conducted in connection with the proposed amalgamation of Gstaad and Claranova, which is intended to constitute Gstaad’s qualifying transaction under Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange.
Resilience Reserve subscribed for 8,400,000 subscription receipts. Upon closing of the transaction and release of escrowed proceeds, Resilience Reserve will hold approximately 18.33% of the resulting issuer shares. Together, Resilience Reserve and Mr. Reid will collectively hold an aggregate of 8,900,000 resulting issuer shares, representing approximately 19.43% of the then outstanding resulting issuer shares.
Cautionary Statements
Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and, if applicable, disinterested shareholder approval.
This news release contains forward-looking statements that are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
